This paper will discuss different definitions of the term “mood stabilizer” and highlight in detail the antiepileptic drugs carbamazepine, valproate and lamotrigine with respect to their relative strengths in stabilizing mood in bipolar patients. These drugs are heterogeneous in their mechanisms of action and in their efficacy to stabilize patients with epilepsy and the various mood states in bipolar disorder. Lamotrigine has obtained approval in several countries for the indication of preventing bipolar depressive episodes, which raises the question of differential efficacy of other antiepileptic drugs as mood stabilizers in the prevention of either depressive or hypo-/manic episodes. A Medline Search to 2006 was conducted for controlled acute and maintenance studies of the three scientifically and clinically most established antiepileptic drugs carbamazepine, valproate and lamotrigine. The medications discussed in this review only partly fulfill definitions of a mood stabilizer, and we suggest that future research should focus on combined treatment strategies.
Sachs G, Bipolar mood disorder: Practical strategies for acute and maintenance phase treatment. J Clin Psychopharmacol1996; 16 (2suppl 1): 32S–47S.
2.
BowdenCL. New concepts in mood stabilization: Evidence for the effectiveness of valproate and lamotrigine. Neuropsychopharmacology1998; 19(3):194–199.
3.
KetterTACalabreseJR. Stabilization of mood from below versus above baseline in bipolar disorder: A new nomenclature. J Clin Psychiatry2002; 63(2): 146–151.
4.
CalabreseJRSheltonMDRapportDJKimmelSEElhajO. Long-term treatment of bipolar disorder with lamotrigine. J Clin Psychiatry2002; 63 (suppl10): 18–22.
5.
GrunzeHSchlösserSWaidenJ. Comment on: Adli M, Bschor T, Canata B, Dopfmer S, Bauer M: Lithium in der Behandlung der akuten Depression. Fortschr Neural Psychiat1998: 66: 435–441. Fortschr Neural Psychiatr 1999; 67(8): 384–386.
6.
GeddesJRBurgessSHawtonKJamisonKGoodwinGM. Long-term lithium therapy for bipolar disorder: Systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry2004; 161(2): 217–222.
7.
ManjiHKMooreGJChenG. Bipolar disorder: Leads from the molecular and cellular mechanisms of action of mood stabilisers. Br J Psychiatry2001; 178 (suppl41): 107–119.
8.
GrunzeHAmannBWaldenJ. How might anticonvulsant drugs work in bipolar affective disorder? In: TrimbleMRSchmitzB, (eds). Seizures, Affective Disorders and Anticonvulsant Drugs. Guildford: Clarius Press, 2002: 117–130.
9.
WilliamsRSChengLMudgeAWHarwoodAJ. A common mechanism of action for three mood-stabilizing drugs. Nature2002; 417(6886): 292–295.
10.
FryeMAKetterTALeverichGSHugginsTLantzCDenicoffKD. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry2000; 61(1): 9–15.
11.
PostRMLeverichGSAltshulerLLFryeMASuppesTMKeckPE. An overview of recent findings of the Stanley Foundation Bipolar Network (Part I). Bipolar Disord2003; 5(5): 310–319.
12.
BrownDSilverstoneTCooksonJ. Carbamazepine compared to haloperidol in acute mania. Int Clin Psychopharmacol1989; 4(3): 229–238.
13.
KleinEBentalELererBBelmakerRH. Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses: A controlled study. Arch Gen Psychiatry1984; 41(2): 165–170.
14.
LererBMooreNMeyendorffEChoSRGershonS. Carbamazepine versus lithium in mania: A double-blind study. J Clin Psychiatry1987; 48(3): 89–93.
15.
LusznatRMMurphyDPNunnCM. Carbamazepine vs lithium in the treatment and prophylaxis of mania. Br J Psychiatry1988; 153: 198–204.
16.
SmallJGKlapperMHMilsteinVKellamsJJMillerMJMarhenkeJD. Carbamazepine compared with lithium in the treatment of mania. Arch Gen Psychiatry1991; 48(10): 915–921.
17.
VasudevKGoswamiUKohliK. Carbamazepine and valproate monotherapy: Feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder. Psycho-pharmacology Berl2000; 150(1): 15–23.
18.
BallengerJCPostRM. Therapeutic effects of carbamazepine in affective illness: A preliminary report. Commun Psychopharmacol1978; 2(2): 159–175.
19.
OkumaTKishimotoAInoueKMatsumotoHOguraA. Anti-manic and prophylactic effects of carbamazepine (Tegretol) on manic depressive psychosis: A preliminary report. Folia Psychiatr Neurol Jpn1973; 27(4): 283–297.
20.
OkumaTInanagaKOtsukiSSaraiKTakahashiRHazamaH. Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: A double-blind controlled study. Psychopharmacology1979; 66(3): 211–217.
21.
OkumaTYamashitaITakahashiRItohHOtsukiSWatanabeS. Comparison of the antimanic efficacy of carbamazepine and lithium carbonate by double-blind controlled study. Pharmacopsychiatry1990; 23(3): 143–150.
22.
BallengerJCPostRM. Carbamazepine in manic-depressive illness: A new treatment. Am J Psychiatry1980; 137(7): 782–790.
23.
WeislerRHKalaliAHKetterTA. A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry2004; 65(4): 478–484.
24.
WeislerRHHirschfeldRCutlerAJGazdaTKetterTAKeckPESwannA, Kalali A; SPD417 Study Group. Extended-release carbamazepine capsules as monotherapy in bipolar disorder: Pooled results from two randomised, double-blind, placebo-controlled trialsCNS Drugs2006; 20(3): 219–231.
25.
ZornbergGLPopeHG. Treatment of depression in bipolar disorder: New directions for research. J Clin Psychopharmacol1993; 13(6): 397–408.
26.
PostRMUhdeTWBallengerJCSquillaceKM. Prophylactic efficacy of carbamazepine in manic-depressive illness. Am J Psychiatry1983; 140(12): 1602–1604.
27.
OkumaTInanagaKOtsukiSSaraiKTakahashiRHazamaH. A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of manic-depressive illness. Psychopharmacology (Berl)1981; 73(1): 95–96.
28.
CabreraJAlbrechtJMüller-OerlinghausenB. Kombinierte rezidiv-prophylaktische Behandlung der manisch-depressiven Erkrankung mit Lithium und Carbamazepin oder Oxcarbazepin. Nervenarzt1987; 58(4): 245–249.
29.
CoxheadNSilverstoneTCooksonJ. Carbamazepine versus lithium in the prophylaxis of bipolar affective disorder. Acta Psychiatr Scand1992; 85(2): 114–118.
30.
DenicoffKDSmith-JacksonEEDisneyERAliSOLeverichGSPostRM. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry1997; 58(11): 470–478.
31.
GreilWLudwig-MayerhoferWErazoNSchöchlinCSchmidtSEngelRR. Lithium versus carbamazepine in the maintenance treatment of bipolar disorders—a randomised study. J Affect Disord1997; 43(2): 151–161.
32.
GreilWKleindienstN. The comparative prophylactic efficacy of lithium and carbamazepine in patients with bipolar I disorder. Int Clin Psychopharmacol1999; 14(5): 277–281.
33.
HartongEGMolemanPHoogduinCABroekmanTGNolenWA. Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. J Clin Psychiatry2003; 64(2): 144–151.
34.
WatkinsSECallenderKThomasDRTidmarshSFShawDM. The effect of carbamazepine and lithium on remission from affective illness. Br J Psychiatry1987; 150: 180–182.
35.
SimhandlCDenkEThauK. The comparative efficacy of carbamazepine low and high serum level and lithium carbonate in the prophylaxis of affective disorders. J Affect Disord1993; 28: 221–231.
36.
GreilWKleindienstN. Lithium versus carbamazepine in the maintenance treatment of bipolar II disorder and bipolar disorder not otherwise specified. Int Clin Psychopharmacol1999; 14(5): 283–285.
37.
EmilienGMaloteauxJMSeghersACharlesG. Lithium compared to valproic acid and carbamazepine in the treatment of mania: A statistical meta-analysis. Eur Neuropsy-chopharmacol1996; 6(3): 245–252.
38.
PopeHGMcElroySLKeckPEHudsonJI. Valproate in the treatment of acute mania: A placebo-controlled study. Arch Gen Psychiatry1991; 48(1): 62–68.
39.
FreemanTWClothierJLPazzagliaPLesemMDSwannAC. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry1992; 149(1): 108–111.
40.
BowdenCLBruggerAMSwannACCalabreseJRJanicakPGPettyF. Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA1994; 271(12): 918–924.
41.
TohenMBakerRWAltshulerLLZarateCASuppesTKetterTA. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry2002; 159(6): 1011–1017.
42.
ZajeckaJMWeislerRSachsGSwannACWozniakPSommervilleKW. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry2002; 63(12): 1148–1155.
43.
Müller-OerlinghausenBRetzowAHennFGiedkeHWaidenJ. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: A prospective, randomized, double-blind, placebo-controlled multicenter study. J Clin Psychopharmacol2000; 20: 195–203.
44.
McElroySLKeckPEStantonSPTugrulKCBennettJAStrakowskiSM. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J Clin Psychiatry1996; 57(4): 142–146.
45.
MacritchieKGeddesJRScottJHaslamDde LimaMGoodwinG. Valproate for acute mood episodes in bipolar disorder. Cochrane Database Syst Rev2003;(1): CD004052.
46.
SachsGCollinsMAAltshulerLKetterTSuppesTRasgonN. Divalproex sodium versus placebo for the treatment of bipolar depression. APA 2002 Syllabus and Proceedings Summary; 2002.
47.
WinsbergMEDe GoliaSGStrongCMKetterTA. Divalproex therapy in medication-naive and mood-stabilizer-naive bipolar II depression. J Affect Disord2001; 67(1–3): 207–212.
48.
DavisLLBartolucciAPettyF. Divalproex in the treatment of bipolar depression: A placebo-controlled studyJ Affect Disord2005; 85(3): 259–266.
49.
LambertPAVenaudG. Comparative study of valpromide versus lithium in the treatment of affective disorders. Nervure1992; 5: 57–62.
50.
BowdenCLCalabreseJRMcElroySLGyulaiLWassefAPettyF. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Divalproex Maintenance Study Group. Arch Gen Psychiatry2000; 57: 481–489.
51.
TohenMKetterTAZarateCASuppesTFryeMAltshulerL. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: A 47-week study. Am J Psychiatry2003; 160(7): 1263–1271.
52.
CalabreseJRSheltonMDRapportDJYoungstromEAJacksonKBilaliS. A 20-month, double-blind, maintenance trial of lithium versus divalproex in rapid-cycling bipolar disorder. Am J Psychiatry2005; 162(11): 2152–2161.
53.
SuppesTBrownESchuhLMBakerRWTohenM. Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: Post hoc analyses of 47-week data. J Affect Disord2005; 89(1–3): 69–77.
54.
BowdenCL. Lamotrigine in the treatment of bipolar disorder. Expert Opin Pharmacother2002; 3(10): 1513–1519.
55.
CalabreseJRBowdenCLSachsGSAscherJAMonaghanERuddG. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry1999; 60: 79–88.
56.
CalabreseJRSuppesTBowdenCLSachsGSSwannACMcElroySL. A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder. Lamictal 614 Study Group. J Clin Psychiatry2000; 61(11): 841–850.
57.
CalabreseJBowdenCLSachsGYathamLNBehnkeKMehtonenO-P. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment In recently depressed patients with bipolar I disorder. J Clin Psychiatry2003; 64(9): 1013–1024.
58.
BowdenCLCalabreseJRSachsGYathamLNAsgharSAHomplandM. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry2003; 60(4): 392–400.
59.
GoodwinGMBowdenCLCalabreseJRGrunzeHKasperSWhiteR. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry2004; 65(3): 432–441.
60.
AmannBGrunzeH. Neurochemical underpinnings in bipolar disorder and epilepsy. Epilepsia2005; 46 (suppl4): 26–30.
61.
RegestaGTanganelliP. Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res1999; 34(2–3): 109–122.
